中文名: Pacific Biosciences of California, Inc. 公司名称: Pacific Biosciences of California, Inc. 所属行业: 健康科技 / 医学专科 交易所: 纳斯达克交易所 股票分析 最近更新于 2025-02-12 1 超过16%的股票 行业排名 186/202 市场排名 4153/4925 机构预测 当前价 $1.360 目标均价 $2.83 最高目...
用富途牛牛查看Pacific Biosciences of California(PACB)的股票价格、即时报价、最新新闻、历史走势图、财务信息和行情。
Pacific Biosciences of California Inc. News Stock Investing News, Analysis and Tips Nov 16, 2023 3:03 PM EST Meet the biotech company Cathie Wood bought half a million shares of this month Its work could make major positive change in the fight against cancer. PSNL Investing News, Analysis, ...
A high-level overview of Pacific Biosciences of California, Inc. (PACB) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
Check Pacific Biosciences of California’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. USD USD PACB Stock Performance Previous close 1.7 Day range 1.69 - 1.87 Year range 1 - 7 Market cap 532,710,000 Primary exchang...
Pacific Biosciences of California, Inc. Common Stock (PACB) Dividend History“股息历史记录”页面是一个单独页面,可查看所有汇总的股息支付信息。请访问我们的股息日历:我们的合作伙伴 Quotemedia 提供了下个月的除息日期。 Data Disclaimer: The Nasdaq Indices and the Major Indices are delayed at least 1 ...
关于Pacific Biosciences of California公司 Pacific Biosciences of California Inc 是一家生物技术公司,专注于设计、开发和制造测序解决方案,使科学家和临床研究人员能够提高对基因组的理解,并最终解决遗传复杂的问题。它在一个可报告的部门运营:开发、制造和营销用于遗传分析的综合平台。该公司的大部分收入来自美洲,其次...
瑞银:下调Pacific Biosciences(PACB.US)评级,由买入调整至中性评级, 目标价2.00美元。 Pacific Biosciences of California(PACB.US)公司简介:Pacific Biosciences of California Inc 是一家生物技术公司,专注于设计、开发和制造测序解决方案,使科学家和临床研究人员能够提高对基因组的理解,并最终解决遗传复杂的问题。它在...
伯恩斯坦研究公司:维持Pacific Biosciences(PACB.US)评级,由优于大市调整至优于大市评级, 目标价由9.00美元调整至2.50美元。 Pacific Biosciences of California(PACB.US)公司简介:Pacific Biosciences of California Inc是一家生物技术公司,专注于生物研究工具的设计,开发和商业化。 该公司开发测序系统以协助解决遗传复...
, June 08, 2020 (GLOBE NEWSWIRE) -- The Board of Directors of Pacific Biosciences of California, Inc. (NASDAQ: PACB) (the “Company”) has announced that it is rescheduling the date of the Company’s 2020 Annual Meeting of Stockholders (the “Annual Meeting”) previously s...